Key result
Cardiac contractility modulation therapy significantly improved exercise capacity and quality of life compared to optimized medical therapy in symptomatic heart failure patients with LVEF 25-45% over 24 weeks.
Why the study?
To synthesize mechanistic insights, clinical evidence, patient selection principles, and practical considerations defining the evolving role of cardiac contractility modulation within contemporary heart failure care pathways.
RCT (n=160)
null
randomized
Yes
Answers are grounded in this paper and cite their sources.
Cardiac contractility modulation is an evolving bioelectronic therapy that improves functional status and quality of life in carefully selected heart failure patients.
Cardiac contractility modulation (CCM) is a bioelectronic therapy that delivers precisely timed electrical signals during ventricular refractoriness to modulate myocardial contractility without triggering depolarization. Unlike pacing-based therapies, CCM does not initiate a new depolarization but instead modulates intracellular signaling pathways to enhance myocardial contractility without increasing myocardial oxygen consumption. CCM therefore represents a myocardial conditioning strategy distinct from cardiac resynchronization therapy, conduction system pacing, or neuromodulation. Experimental and translational studies demonstrate that repeated CCM delivery induces sustained myocardial adaptations, including improvements in excitation–contraction coupling, molecular signaling pathways, and structural remodeling that extend beyond transient hemodynamic effects. Across clinical investigations, CCM has been associated with meaningful improvements in exercise tolerance, health-related quality of life, and functional status in carefully selected populations. Observational data further suggest a potential reduction in heart failure-related hospitalizations when therapy is applied within evidence-aligned indications. Recent technological developments—including simplified ventricular lead configurations, rechargeable compact generators, and integrated CCM–defibrillator platforms—have reduced procedural complexity and may broaden clinical applicability, particularly in patients with concomitant implantable cardioverter–defibrillator indications. This review synthesizes mechanistic insights, clinical evidence, patient selection principles, and practical considerations to define the evolving role of CCM within contemporary heart failure care pathways.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) conducted an RCT in Symptomatic heart failure patients with NYHA class III, left ventricular ejection fraction 25-45%, not candidates for cardiac resynchronization therapy, with narrow QRS duration (n=160). Cardiac contractility modulation (CCM) therapy vs. Optimized medical therapy alone was evaluated on Change in peak VO2, 6-minute walk distance, and Minnesota Living with Heart Failure Questionnaire (MLWHFQ) score from baseline to 24 weeks (significant improvement in CCM group vs control). Cardiac contractility modulation therapy significantly improved exercise capacity and quality of life compared to optimized medical therapy in symptomatic heart failure patients with LVEF 25-45% over 24 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: